John F. Sheridan - 15 May 2024 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role
PRESIDENT & CEO, Director
Signature
/s/ Rachel Malina, Attorney-in-Fact for John F. Sheridan
Issuer symbol
TNDM
Transactions as of
15 May 2024
Net transactions value
-$487,300
Form type
4
Filing time
17 May 2024, 17:45:51 UTC
Previous filing
29 Feb 2024
Next filing
28 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNDM Common Stock Award $15,296 +978 +3.3% $15.64 30,866 15 May 2024 Direct F1
transaction TNDM Common Stock Options Exercise $0 +792 +2.6% $0.000000 31,658 15 May 2024 Direct
transaction TNDM Common Stock Tax liability $19,043 -402 -1.3% $47.37 31,256 15 May 2024 Direct F2
transaction TNDM Common Stock Options Exercise $0 +2,237 +7.2% $0.000000 33,493 15 May 2024 Direct
transaction TNDM Common Stock Tax liability $53,718 -1,134 -3.4% $47.37 32,359 15 May 2024 Direct F2
transaction TNDM Common Stock Options Exercise $0 +21,886 +68% $0.000000 54,245 15 May 2024 Direct
transaction TNDM Common Stock Tax liability $429,835 -9,074 -17% $47.37 45,171 15 May 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNDM Restricted Stock Unit Options Exercise $0 -792 -20% $0.000000 3,170 15 May 2024 Common Stock 792 Direct F3, F4, F5
transaction TNDM Restricted Stock Unit Options Exercise $0 -2,237 -20% $0.000000 8,945 15 May 2024 Common Stock 2,237 Direct F4, F6, F7
transaction TNDM Restricted Stock Unit Options Exercise $0 -21,886 -33% $0.000000 43,773 15 May 2024 Common Stock 21,886 Direct F8, F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 16, 2023 through May 15, 2024. This transaction is also exempt under Rule 16b-3(c).
F2 Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
F3 Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).
F4 Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
F5 RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.
F6 Awarded on May 25, 2022 pursuant to the 2013 Plan.
F7 RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
F8 Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan).
F9 Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F10 RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.